Neoplasias Mieloproliferativas

Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B, Volume 366 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors. Sections cover Genetic and Sex predisposition to MPN, Transcriptional configurations of Myeloproliferative Neoplasms, Inhibitors and therapeutic targets of MPN, Mutational landscape of blast-phase myeloproliferative neoplasm (MPN-BP) and antecedent MPN, and Lessons from Mouse model of MPN, Lab tests for MPN. Publishes only invited review articles on selected topics Authored by established and active cell and molecular biologists from international sources Offers a wide range of perspectives on specific subjects

Introduction The understanding of the genetic, epigenetic, immuno- well as for practicing hematologists or oncologists. logical and biological causes of myeloproliferative dis- Each chapter follows a similar architecture and leads orders has substantially improved in the last few years. through epidemiology, genetic and molecular causes, Together with refined tools in pathology, the successful hematological and clinical findings, prognostic factors establishment of mouse models mimicking at least some and current treatment approaches of the diseases. of the myeloproliferative disorders, and murine models Effort has been made to point out the evolving field of novel drugs in this arena but simultaneously diff- allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to entiate between standard and experimental treatment ever increasing numbers of modified classification approaches. schemes. It is therefore important for the heamtologist Together with the co-editors and all the authors of or oncologist to keep up with this rapid change in classi- the various chapters I hope that the readers of the book fication language, the upcoming of new entities or differ- will enjoy reading and benefit from the information entiation between, or subclassification of, rare diseases provided.

Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A, Volume 365 in the International Review of Cell and Molecular Biology series reviews and details current advances in cell and molecular biology. Chapters in this new release include MPN a continuum of different disease entities, Bone marrow microenvironment of MPN, Extramedullary hemopoiesis in MPN, The JAK2 mutation, Calreticulin mutations in myeloproliferative neoplasms, and Cytogenetic abnormalities and non-driver mutations in MPN. The IRCMB series has a worldwide readership, maintaining a high standard by publishing invited articles on important and timely topics that are authored by prominent cell and molecular biologists. The articles published in IRCMB have a high impact and an average cited half-life of 9 years. This great resource ranks high amongst scientific journals dealing with cell biology. Publishes only invited review articles on selected topics Authored by established and active cell and molecular biologists and drawn from international sources Offers a wide range of perspectives on specific subjects

This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.

Provides clear, broad and comprehensive guidance across common and rare MPNs for both day-to-day management and special situations.

This new series on the treatment of cancer is sponsored by the VICe. The editors and authors feel strongly that more standardiza tion is needed on a worldwide basis in cancer therapy. This, of course, is only possible if experts from all countries subscribe to a joint policy of making their treatment designs available to practising oncologists all over the world. Current Treatment of Cancer will discuss all the equipment and methods now in use in cancer therapy. It will cover all types of cancer, thus providing the reader with comprehensive information on cancer management. In recent decades there has been a tremendous improvement in the treatment of cancer, and there is hope for even further success in this fight. We are convinced that this series will help us to make a concerted response to the challenge of cancer. VICC Treatment and Rehabilitation Programme Ismail Elsebai Chairman VII Preface During the past two decades we have witnessed an exciting evolution in the un derstanding and management of hematologic malignancies. The number of drugs available 20 years ago for the treatment of acute leukemia was so small that the disease in children and in adults could be discussed within one chapter. Since then, rapid progress has been made in the management of childhood leukemia, making for a much better prognosis. Over the past 10 years we have seen the same developments in respect of leukemia in adults.

With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeuti